HomeQuestion

What alternative adjuvant therapy do you recommend to an imatinib intolerant patient with high-risk GIST?

1

Join the Discussion

Discuss the cases and questions guidelines don't cover.

Related Questions

With recent PFS data from LEAP-012 and Emerald-1, do you routinely offer for patients with intermediate BCLC stage HCC undergoing TACE or TARE systemic therapy (pembro/lenva or durve/bev)?

What would your approach be for a locally advanced head and neck cancer diagnosed concurrently with a mid-esophageal cancer?

Why does NCCN still not recommend using circulating tumor DNA to guide adjuvant chemotherapy in stage II colon cancer when colon cancer experts are currently embracing the practice?

In a patient with esophageal cancer with lymph node involvement, would you consider treating with definitive chemo-radiation if they have a single area of retroperitoneal metastasis?

How do you treat metastatic BRAF-mutated small bowel adenocarcinoma in the first-line setting?

Evidence Meets Expertise

For Physicians

Mednet AI
Community

Company

About
Careers
Publications
Blog

Support

FAQs
Code of Conduct
AI Community Guidelines
Contact Us
Programs

Legal

Privacy Policy
Terms of Service

© 2026 Mednet Inc. All rights reserved.